Amgen (AMGN) Announces BLINCYTO Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

Go back to Amgen (AMGN) Announces BLINCYTO Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia
Amgen Inc (NASDAQ: AMGN) Delayed: 254.21 +2.91 (1.16%)
Previous Close $251.30    52 Week High $176.85 
Open $251.78    52 Week Low $133.64 
Day High $255.70    P/E 38.28 
Day Low $251.78    EPS $6.64 
Volume 2,513,028